REPLIMUNE GROUP, INC. Total Long-Term Debt
REPLIMUNE GROUP, INC. (REPL) had Total Long-Term Debt of $44.43 million as of 2023-12-31, per its 10-Q filed 2024-02-08.
Discontinued › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2024-02-08
- 2023-12-31: Long-term Debt $44.43M.
- 2023-09-30: Long-term Debt $29.16M.
- 2023-06-30: Long-term Debt $28.91M.
- 2023-03-31: Long-term Debt $28.65M.
| Period end | Long-term Debt |
|---|---|
| 2023-12-31 | $44.43M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $29.16M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $28.91M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $28.65M 10-Q · filed 2024-02-08 |
| 2022-12-31 | $28.39M 10-Q · filed 2023-02-09 |
| 2022-03-31 | $0.00 10-Q · filed 2023-02-09 |
| 2020-09-30 | $9.83M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $9.76M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $9.80M 10-K · filed 2021-05-20 |
| 2019-12-31 | $9.74M 10-Q · filed 2020-02-13 |
| 2019-09-30 | $9.66M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |